https://www.hmpgloballearningnetwork.com/site/onc/quiz/anti-gprc5d-car-t-cell-therapy-relapsedrefractory-mm
Anti-GPRC5D CAR T-Cell Therapy for Relapsed/Refractory MM
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?...
car t cell therapyantigprc5drelapsedrefractory
https://www.jnj.com/media-center/press-releases/janssen-presents-updated-results-evaluating-first-in-class-gprc5d-bispecific-antibody-talquetamab-in-heavily-pretreated-patients-with-multiple-myeloma
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab...
Jul 18, 2025 - Updated results for talquetamab monotherapy and in combination with daratumumab highlighted in oral presentations at the 2022 EHA Annual Congress